With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., March 9, 2021 /PRNewswire/ The time of Tune In… Turn On… and Dropout psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds… they were universally declared taboo. My, but how times have changed now that the baby boomers are old and want treatments for what life is bringing them now… new, effective treatments. Psychedelic medicine is one of the fastest growing markets. Psychedelic Medicines also called as hallucinogenics, are a group of substances including chemicals, such as LSD, and plants that are used in the treatment of various mental disorders such as resistant depression, panic disorder, opiate addiction, etc. These are used to change and enhance sensory perceptions, energy levels, thought pr
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Psychedelics and mental health company
The Series D funding round is being touted as the psychedelics sector’s largest to date.
Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel.
Apeiron Investment Group and Woodline Partners LP also participated.
Atai’s portfolio companies are researching 13 different psychedelic and non-psychedelic compounds for the treatment of a wide range of mental health disorders. Atai is an early investor and holds a significant stake in
Compass Pathways (NASDAQ: CMPS).
Last November, Atai closed a Series C financing round for $125 million. A spokesperson told Benzinga that the company is expected to list on NASDAQ during 2021, but exact dates are still to be confirmed.
Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of Magic Mushrooms Benzinga 3/8/2021
Psychedelics and mental health company
Popular Searches
The Series D funding round is being touted as the psychedelics sector’s largest to date.
Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel.
Apeiron Investment Group and Woodline Partners LP also participated.
Atai’s portfolio companies are researching 13 different psychedelic and non-psychedelic compounds for the treatment of a wide range of mental health disorders. Atai is an early investor and holds a significant stake in
Share:
The Company expects to have ibogaine manufactured and in use for research by Q4.
VANCOUVER, BC, March 3, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE:MCUR) (OTCQB:MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research.
Ibogaine is a naturally occurring psychoactive compound extracted from the root of the
Tabernanthe iboga shrub
, native of the Congo and Gabon.
1 The compound offers therapeutic potential for substance use disorders, and is claimed to be among the most powerful anti-addiction drugs, particularly when used with proper supervision and support. However, natural sources of ibogaine are extremely limited since these plants are at risk of extinction due to the growing global demand and environmental pressures threatening their natural ha